Cardiovascular 1
Cardiovascular 2
Cardiovascular 3
Cardiovascular 4
Cardiovascular 5
100

Treatment of atrial myxoma

Surgical excision

100

Most common cause of HFpEF

Hypertension

100

Most effective drug therapy for hypertriglyceridemia

Fenofibrate

100

TTE surveillance frequency in asymptomatic HCM

Every 1-2 years

100

Primary CV side effect of bevacizumab

Hypertension

200

Physical findings in chronic mitral regurgitation

Blowing holosystolic murmur, systolic click, S3, lateral displacement of apical impulse

200

Alternative treatment for patients with HFrEF intolerant of ACE inhibitors or ARBs

Isosorbide dinitrate-hydralazine

200

Aortic atheroma treatment

Antiplatelet agent and statin

200

Management of TAA with diameter <5.0 cm

β-Blockers with target BP <130/80 mm Hg

200

Recommended heart valve type for patients older than 65 years

Bioprosthesis

300

Treatment of recurrent or chronic pericarditis with a noninflammatory phenotype

Glucocorticoids

300

Most common ECG findings in HCM

Increased QRS voltage, left atrial enlargement, LV conduction abnormalities, pathologic Q waves, repolarization abnormalities

300

Criteria for adding to maximal statin therapy in secondary ASCVD prevention in patients not considered at very high risk

LDL cholesterol level ≥70 mg/dL or <50% reduction in LDL

300

RV failure, normal BNP, pericardial thickening

Constrictive pericarditis

300

Complication if ACE inhibitor is discontinued <36 hours before valsartan-sacubitril is started

Angioedema

400

Treatment of acute pericarditis

NSAIDs plus colchicine

400

Cardiomyopathy associated with apical dyskinesis or ballooning

Takotsubo (stress) cardiomyopathy

400

Duration of DAPT after ACS

At least 12 months

400

Diagnostic criteria for acute pericarditis

Pleuritic chest pain plus one of the following: pericardial friction rub, new ECG changes, new effusion, inflammatory biomarker elevation, imaging indicative of pericardial inflammation

400

Fever, myalgia, and respiratory symptoms followed by HF

Viral myocarditis

500

Cardiac biomarker to distinguish restrictive cardiomyopathy (elevated) from constrictive pericarditis (normal)

BNP

500

Drugs indicated for all NYHA functional classes of HFrEF

β-Blockers, specifically bisoprolol, carvedilol, or metoprolol succinate, and ACE inhibitors

500

Syndrome of angina and normal coronary arteries

Cardiac syndrome X (microvascular angina)

500

Baseline ECG abnormalities that warrant imaging along with stress testing

ST segment depression, LVH, LBBB, digitalis effect, preexcitation, paced beats

500

Life-prolonging therapy for severe aortic stenosis

Aortic valve replacement

M
e
n
u